Form 4 for ABCL AbCellera Biologics Inc.
Accepted 2021-09-02 00:00:00 ET · period of report 2021-08-31 · accession 0001209191-21-054543 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2021-09-02 | 2021-08-31+ | ABCL | HAMER JOHN | Dir | S - Sale | $16.94 | -300.0K | 266.2K | -53% | -$5.08M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2021-09-01 | S | D | 137,351 | $16.93 | 128,862 | D | — | — | (F3) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $16.56 and $17.38. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. (F2) Effective August 20, 2021, DCVC Bio GP, LLC ("DCVC Bio GP"), distributed 428,862 common shares of the Issuer to John Hamer in connection with a pro-rata distribution for no consideration to the members of DCVC Bio GP. |
| 2 | Common | Common Shares | 2021-08-31 | S | D | 162,649 | $16.95 | 266,213 | D | — | — | (F1) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $16.64 and $17.51. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. (F2) Effective August 20, 2021, DCVC Bio GP, LLC ("DCVC Bio GP"), distributed 428,862 common shares of the Issuer to John Hamer in connection with a pro-rata distribution for no consideration to the members of DCVC Bio GP. |